Loading stock data…
$2.35-0.06 (-2.29%)
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
Zentalis Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.35 with a market capitalization of $382M. Wall Street consensus targets $7.44 (9 analysts), implying a +217.5% move over the next 12 months. The stock is currently near its 52-week low of $1.21, remaining 32.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$44.39M↓ | -$37.85M↓ | -$37.39M↓ | -$33.73M↑ | -$36.06M |
| Net Income | -$42.29M↓ | -$35.35M↓ | -$35.22M↓ | -$26.69M↑ | -$26.87M |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 cl...